42,476 XNAS Volume
XNAS 18 Mar, 2025 11:18 AM (EDT)
Silence Therapeutics Plc -... Key Metrics
Default
All financials are in USD Million and price data in USD
VIEW MORE
Low Financial Strength
Expensive Valuation
Technically Bearish
Weak Stock
These stocks are the ones with poor quality, financials and technicals. This indicates that investors should be highly watchful with these stocks.
View Similar
Embed DVM
Check Before You Buy
VIEW FULL CHECKLISTMedium rank
6Positive12Negative
33.3% Pass in checklist
Check P/E Buy Sell Zone
This stock has negative PE
Silence Therapeutics Plc -... Stock Price Analysis
Day Price Range | 3.9 (LTP) 3.74 LowHigh |
Week Price Range | 3.9 (LTP) 3.74.6 LowHigh |
Month Price Range | 3.9 (LTP) 3.75.3 LowHigh |
52 Week Price Range | 3.9 (LTP) 3.724.7 LowHigh |
Silence Therapeutics Plc -... Live Price Chart
Switch to TradingView
Fetching data ...
Revenue forecast
Miss
Silence Therapeutics Plc - ADR's Revenue was lower than average estimate 2 times in past 3 years
EPS forecast
Current EPS
Avg. Estimate
Miss
EPS is expected to reduce by 4.0% in FY25
Consensus Recommendation
7 ANALYST Recommendations
BUY
The consensus recommendation from 7 analysts for Silence Therapeutics Plc - ADR is BUY
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get Silence Therapeutics Plc -... Stock Analysis
Silence Therapeutics Plc -... stock analysis with key metrics, changes, and trends.
| Silence Therapeutics Plc -... Metric | VALUE | CHANGE % | TREND | ANALYSIS | |
|---|---|---|---|---|---|
| Annual Revenue | $43.26 M | 36.71% | positive |
| |
| Annual Net Profit | $45.31 M | 16.45% | positive |
| |
| Price to Earning Ratio | -4.22 | - | negative |
| |
| Stock Price | $3.93 | -82.79% | negative |
| |
| Quarterly Revenue | $24.33 M | 649.9% | positive |
| |
| Quarterly Net profit | $14.17 M | 174.51% | positive |
| |
| Mutual Fund Holding | 2.67 % | -0.72% | negative |
| |
| Institutional Holding | 48.87 % | -7.51% | negative |
| |
Loading data..
Silence Therapeutics Plc - ADR - Company Profile
What does Silence Therapeutics Plc - ADR do?
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Silence Therapeutics Plc - ADR Board of directors
All Gross Remunerations are in USD